Akebia Therapeutics, Inc. (AKBA): debt financing — Akebia draws $9.3M net from extended loan tranche; issues warrant for 1.15M shares

Akebia Therapeutics, Inc.

Extended Tranche C expiry from Dec 31, 2024 to Feb 3, 2025; interest accrues from Dec 31, 2024.
Drew $10M Tranche C on Feb 3, 2025; net proceeds of $9.3M after debt issuance costs and interest.
Issued warrant to Kreos Capital affiliate for 1,153,846 shares at $1.30 exercise, 8-year term.
Warrant not registered; relies on Section 4(a)(2) and Rule 506(b) exemption.
Loan facility total $55M; prior tranches of $37M and $8M already drawn.

item 1.01 item 2.03 item 3.02

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Akebia Therapeutics, Inc. incurred term loan of $10.0 million with Kreos Capital VII (UK) Limited.

Instrument: term loan
Principal: $10.0 million
Counterparty: Kreos Capital VII (UK) Limited
Event: incurrence

Exact text from the filing

tranche of $37.0 million, which was funded on January 29, 2024, (ii) an additional tranche of $8.0 million, which was funded on April 19, 2024, and (iii) a final tranche of $10.0 million, which was available in a single draw through an expiry date of December 31, 2024 (the “Prior Tranche C Loan”). As a result of the Second Amendment, the Prior Tranche C Loan

View on SEC.gov

Browse all debt financings →

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001517022-25-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.